Adalta Ltd has released a press release.
Corporate Presentation
Filed with ASX ·
6ix hasn’t read this filing yet.
In the deck
Story so far
Earlier from AdAlta
- Positive AD-214 Phase I extension study results
- January 2024 partnering presentations and progress
- New malaria inhibiting i-body
- Chair address and CEO presentation to AGM
- AD-214 Phase I extension clinical study - interim results
Later from AdAlta
- SYNThesis BioVentures MoU for cellular immunotherapies
- SYNBV MoU Webinar presentation
- Institutional investment to pursue strategic initiatives
- Extension of Victorian Government RDTI Loan Facility
- Cellular immunotherapy manufacturer secured - Cell Therapies
Follow AdAlta into a list and get an email when it puts out news.
Follow AdAlta